Henlius Expands Its Global Reach with U.S. Launch of HANQUYOU

Henlius Launches First Shipment of HANQUYOU to the U.S.

Henlius has achieved a significant milestone with the shipment of HANQUYOU to North America, providing high-quality and affordable treatment options for patients. This marks the company's inaugural product export to the U.S., broadening its commercial supply to include various regions around the world. The introduction of HANQUYOU is seen as a pivotal step in Henlius' global expansion strategy.

Overview of HANQUYOU's Impact

HANQUYOU, Henlius' trastuzumab biosimilar, is officially approved in over 50 countries, benefiting more than 220,000 patients globally. The successful delivery to the United States symbolizes the commitment of Henlius to improving access to essential medicines for patients dealing with HER2-positive breast and gastric cancers.

Leadership Statements on Global Expansion

Ms. Wei Huang, the President of Henlius, remarked that "The entry of HANQUYOU into the U.S. market not only solidifies our international presence but also establishes a foundation for our future product globalization efforts. Since its 2020 launch, approximately 6.5 million units of HANQUYOU have been globally shipped, demonstrating our enhanced production capabilities aimed at benefiting more patients."

Commitment to Quality

Dr. Frank Ye, Vice President and Chief Quality Officer of Henlius, emphasized the importance of high-quality standards to succeed on the global platform. He stated, "Quality is essential for building customer trust and ensuring our products can thrive in international markets. Our focus remains on delivering high-quality biologics to more patients, as medicine quality is critical to patient lives."

Global Presence and Future Directions

Approved in key regions, including the U.S., United Kingdom, Canada, France, Germany, Australia, and others, HANQUYOU is a product with a robust global footprint. The medication is reimbursed nationally in several of these countries, ensuring accessibility for patients who need it most. Henlius has built a resilient quality management system across its multiple production facilities, ensuring compliance with international standards and regulatory requirements.

Strategic Partnerships

A strategic alliance with Intas and its subsidiary, Accord, has been pivotal for Henlius in launching HANQUYOU. The partnership with leading global biopharmaceutical companies demonstrates Henlius' proactive approach in establishing a commercial presence for HANQUYOU. The company is committed to enhancing collaborations with global partners to expedite the introduction of more high-quality medicines worldwide.

Vision of Henlius for Future Innovations

Henlius is more than just a biopharmaceutical company; it is a leader in innovation, aiming to provide affordable and effective biologic therapies for serious health issues, focusing on oncology, autoimmune diseases, and ophthalmic diseases. Since its founding, the company has launched six products within the domestic market and secured approvals for three in international markets, showcasing a strong pipeline of 50 molecules currently under exploration.

Contributions to Global Health

Since its establishment, Henlius has actively worked towards developing a comprehensive and innovative product portfolio, enhancing treatment options for diseases where patient access is essential. The progress in clinical research highlights the company’s commitment to benefiting patients not just locally, but on a global scale.

Frequently Asked Questions

What is HANQUYOU?

HANQUYOU is a trastuzumab biosimilar developed by Henlius, approved in over 50 countries to provide treatment for HER2-positive breast and gastric cancers.

How does Henlius ensure the quality of HANQUYOU?

Henlius has implemented a rigorous quality management system that meets international standards and has undergone numerous inspections and audits by regulatory agencies.

In which regions is HANQUYOU approved?

HANQUYOU is approved in the U.S., UK, Canada, various European countries, and several regions in Asia, including China.

What are Henlius' future plans?

Henlius aims to continue expanding its international footprint and collaborate with global partners to launch additional high-quality medicines.

How has HANQUYOU benefited patients worldwide?

HANQUYOU has provided affordable access to effective treatment options for over 220,000 patients globally, transforming the landscape of cancer care.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.